Veracyte (VCYT)
Healthcare
Close on Nov 5, 2026 (from our latest article): $24.00
- Market value
- $1.9Bat the Nov 5 close
- Revenue growth
- +17%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- 28%12 months to Sep 30, 2026 (10-Q)
- Net cash
- $371Mat Sep 30, 2026
- Worst fall since listing
- −81.2%Feb 9, 2021 to Oct 20, 2022; not back to that high (−69.2% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
What the filings say about the story, dilution and cash runway.
No Long View yet. Request one →
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
More of our coverage that names Veracyte
Long-term fundamentals
Annual results for Veracyte, FY2011–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $3M in FY2011 to $517M in FY2025.
Free cash flow was positive in 3 of the 15 years shown; FY2025: $127M.
Margins
Operating margin was 11% in FY2025, vs −30% in FY2020.
Gross margin was 70% in FY2025, vs 59% in FY2022.
Diluted share count
The diluted share count rose 51% from FY2020 to FY2025, to 81M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $517M | 70% | 11% | $66M | $136M | $10M | $127M |
| FY2024 | $446M | 67% | 4% | $24M | $75M | $11M | $64M |
| FY2023 | $361M | 64% | −24% | −$74M | $44M | $10M | $34M |
| FY2022 | $297M | 59% | −14% | −$37M | $8M | $9M | −$1M |
| FY2021 | $220M | — | −37% | −$76M | −$32M | $5M | −$37M |
| FY2020 | $117M | — | −30% | −$35M | −$10M | $3M | −$13M |
| FY2019 | $120M | — | −13% | −$13M | −$3M | $3M | −$6M |
| FY2018 | $92M | — | −24% | −$23M | −$14M | $2M | −$15M |
| FY2017 | $72M | — | −37% | — | −$24M | $2M | −$26M |
| FY2016 | $65M | — | −44% | — | −$28M | $4M | −$32M |
| FY2015 | $50M | — | −68% | — | −$27M | $6M | −$33M |
| FY2014 | $38M | — | −76% | — | −$28M | $2M | −$30M |
| FY2013 | $22M | — | −106% | — | −$19M | $1M | −$20M |
| FY2012 | $12M | — | −163% | — | −$7M | $1M | −$9M |
| FY2011 | $3M | — | −577% | — | −$14M | $0.3M | −$14M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 81M | $413M | — | $44M | — | — |
| FY2024 | 78M | $289M | — | $36M | — | — |
| FY2023 | 73M | $216M | — | $33M | — | — |
| FY2022 | 72M | $179M | — | $27M | — | — |
| FY2021 | 68M | $173M | $1M | $23M | — | — |
| FY2020 | 53M | $349M | $0.8M | $13M | — | — |
| FY2019 | 46M | $159M | $0.7M | $10M | — | — |
| FY2018 | — | $78M | $25M | $6M | — | — |
| FY2017 | — | $34M | $25M | $7M | — | — |
| FY2016 | — | $59M | $25M | $6M | — | — |
| FY2015 | — | $39M | $5M | $6M | — | — |
| FY2014 | — | $35M | $5M | $4M | — | — |
| FY2013 | — | $71M | $5M | $1M | — | — |
| FY2012 | — | $14M | — | — | — | — |
| FY2011 | — | $8M | — | — | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 5, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | VCYT | S&P 500 |
|---|---|---|
| 2019 | +121.9% | +31.5% |
| 2020 | +75.3% | +18.4% |
| 2021 | −15.8% | +28.7% |
| 2022 | −42.4% | −18.1% |
| 2023 | +15.9% | +26.3% |
| 2024 | +44.0% | +25.0% |
| 2025 | +6.3% | +17.9% |
| 2026 to date | −40.5% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Healthcare
- IRTC iRhythm Down 30.7%
- LEGN Legend Down 16%
- PACB PacBio Down 11.4%
- IBRX ImmunityBio Down 17.7%
- IDXX IDEXX Laboratories Up 21.8%
Questions about Veracyte
- Why did Veracyte stock fall on Nov 5, 2026?
- Veracyte beat third-quarter forecasts, but its main product, the Decipher prostate cancer test, fell short of its own expectations again, and it expects only mid-single-digit revenue growth in 2027 after about 15% this year. The shares fell about 54%, their biggest one-day fall in at least 10 years (Nasdaq closes, our calculation), on a day the S&P 500 fell 4.4%. They were already down more than 40% at the open; no source we found explains the further slide, though the market's fall may have added to it. Read the article →